Summit Therapeutics Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Summit Therapeutics Inc. (SMMT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.85 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-02-20
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-12-31 was $575.00K, a 97.59% increase year-over-year.
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-09-30 was $567.00K, a 41.04% increase year-over-year.
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-06-30 was $425.00K, a 63.46% increase year-over-year.
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $285.00K, a 4.36% decline year-over-year.
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.85M, a 48.04% increase from fiscal 2022.
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.25M, a 12.91% increase from fiscal 2021.
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $1.11M, a 145.68% increase from fiscal 2020.
- Summit Therapeutics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $451.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 11 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.14M derived: sum of 2 quarters · filed 2024-02-20 | $1.57M derived: sum of 3 quarters · filed 2024-02-20 | $1.85M 10-K · filed 2024-02-20 | ||
| 2023-09-30 | $567.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $992.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.28M 10-Q · filed 2023-11-07 | $1.57M derived: sum of 4 quarters · filed 2024-02-20 | ||
| 2023-06-30 | $425.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $710.00K 10-Q · filed 2023-08-09 | $1.00M derived: sum of 3 quarters · filed 2024-02-20 | $1.40M derived: sum of 4 quarters · filed 2024-02-20 | ||
| 2023-03-31 | $285.00K 10-Q · filed 2023-05-11 | $576.00K derived: sum of 2 quarters · filed 2024-02-20 | $978.00K derived: sum of 3 quarters · filed 2024-02-20 | $1.24M derived: sum of 4 quarters · filed 2024-02-20 | ||
| 2022-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $693.00K derived: sum of 2 quarters · filed 2024-02-20 | $953.00K derived: sum of 3 quarters · filed 2024-02-20 | $1.25M 10-K · filed 2024-02-20 | ||
| 2022-09-30 | $402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $662.00K derived: sum of 2 quarters · filed 2023-11-07 | $960.00K 10-Q · filed 2023-11-07 | $1.30M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $260.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $558.00K 10-Q · filed 2023-08-09 | $901.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.20M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | $298.00K 10-Q · filed 2023-05-11 | $641.00K derived: sum of 2 quarters · filed 2023-05-11 | $936.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.25M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $343.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $638.00K derived: sum of 2 quarters · filed 2023-03-09 | $956.00K derived: sum of 3 quarters · filed 2023-03-09 | $1.11M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $613.00K derived: sum of 2 quarters · filed 2022-11-09 | $765.00K 10-Q · filed 2022-11-09 | $964.00K derived: sum of 4 quarters · filed 2022-12-21 | ||
| 2021-06-30 | $318.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $470.00K 10-Q · filed 2022-08-11 | $669.00K derived: sum of 3 quarters · filed 2022-12-21 | $734.00K derived: sum of 4 quarters · filed 2022-12-21 | ||
| 2021-03-31 | $152.00K 10-Q · filed 2022-05-11 | $351.00K derived: sum of 2 quarters · filed 2022-12-21 | $416.00K derived: sum of 3 quarters · filed 2022-12-21 | $491.00K derived: sum of 4 quarters · filed 2022-12-21 | ||
| 2020-12-31 | $199.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $264.00K derived: sum of 2 quarters · filed 2022-12-21 | $339.00K derived: sum of 3 quarters · filed 2022-12-21 | $451.00K 10-K/A · filed 2022-12-21 | ||
| 2020-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $140.00K derived: sum of 2 quarters · filed 2021-11-15 | $252.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $187.00K 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | $112.00K 10-Q · filed 2021-05-17 | |||||
| 2019-12-31 | $347.00K 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | -$69.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | $283.00K 10-Q · filed 2020-11-16 | ||||
| 2019-06-30 | $352.00K 8-K · filed 2020-09-29 | |||||
| 2019-01-31 | $443.00K 10-K · filed 2021-03-31 | $187.00K 8-K · filed 2020-09-29 | ||||
| 2018-01-31 | $184.00K 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |